Bioethicist Vs. Germline Editing Entrepreneur Sparks Uneven Debate
Starting right now. Debate between I. Glenn Cohen (Harvard/reprogenetic bioethics) vs. Cathy Tie, 'serial' human germline editing startup entrepreneur. This should not be an fair fight, but Glenn Cohen is a nice guy...so https://t.co/qfqivoLvhV
Metformin Fails to Boost Walking Distance in PAD Patients
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial "Among people with PAD without diabetes, metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support metformin...
Invest in Affordable At‑Home Diagnostics for Urgent Health Needs
@AnywhereDx is hosting an in person event near Boston on Monday to talk about investing in a future that helps consumers tackle some of their most urgent common health problems inexpensively and accessibly through at-home diagnostics See link https://t.co/7SJlx9vBvJ https://t.co/xVrBWUb8nW
FDA Approves First Free Gene Therapy Restoring Deaf Children's Hearing
JUST IN: FDA approves first ever gene therapy that restores hearing in children born deaf, with treatment available at no cost
Obese HFpEF Patients Show Sarcom
In people with HFpEF (heart failure with preserved ejection fraction) and severe obesity, there is a heart muscle cell defect with sarcomere hyper-phosphorylation. Besides weight loss, sarcomere enhancers (not yet studied) may help. @ScienceMagazine https://t.co/or9VaPjD8J https://t.co/FG98KIzIfN
AI Learns From Millions of Genomes, Not Text
What if you could train a ChatGPT-style AI not on text from the internet, but on millions of genomes across all of life? Samuel King has spent his @Stanford PhD building exactly that. He'll be on the "Genome as a Canvas" panel...
AI-Driven Synthetic Evolution Accelerates Biological Design
Evolution is the most powerful optimization algorithm ever run. It just takes billions of years. Researchers are now rewriting the code. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here:...
Regeneron Approves Free Gene Therapy, Sparks Industry Precedent Worries
$REGN wins FDA approval for its gene therapy to treat a very rare genetic form of hearing loss. The company is giving away the therapy for free. OTOF-related hearing loss affects approx. 50 newborns per year, so really rare, but......
Roche Bets on Cancer and Obesity Drugs Amid Biosimilar Pressure
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs https://t.co/IIt0INA9sI @ByJonGardner $RHHBY
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/n2tSuJXS5b
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/VPIH8iphVP
Phase 3 Trial Tests Daratumumab Reg
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/xv1RlCv8gl
Backing Coherence Neuro's Real Solution for Glioblastoma
A great look at @coherenceneuro, a company we've been backing since 2024. Coherence is actually building something useful for a real market; the thousands of people who get diagnosed with glioblastoma - one of the deadliest brain cancers - each...
Tech Giants Converge on AI‑Biology at SynBioBeta 2026
Silicon Valley's biggest tech players aren't just watching synthetic biology from a distance. They're showing up in person. This year at @SynBioBeta 2026, delegations from @Amazon, @Google, @Apple, @OpenAI, @Anthropic, @NVIDIA, and others are coming to San Jose to see what's...
Gene Therapy Cures Specific Deafness—A Modern Miracle
Another modern miracle: Gene therapy cures a form of deafness. Harvard to USA: You're welcome. https://t.co/mfEzVMGugp
Implant Keeps Drug‑Producing Cells Alive for a Month
A new bioelectronic implant can support populations of three different drug-producing cells for more than a month, keeping them supplied with the correct amounts of oxygen. These cells could produce drugs to treat various cancers, autoimmune diseases like arthritis, and...
Lab‑grown Sperm Creates Embryos, Easing Dystopian Fears
Lab-grown sperm used to create embryos for the first time. Good news if you were worried about the Handmaid's Tale trajectory. https://t.co/q6gItYuGoJ
Half of NMN Supplements Mislabelled, May Harm Users
David Sinclair's research helped turn NMN into a billion-dollar industry. Now he says roughly half the products don't contain what's on the label - and some contain ingredients that could harm you Firstly, NMN (nicotinamide mononucleotide) is a molecule that converts to...
Hims Secures GLP Deals, Positioning for Retatrutide Boom
This is massively good news for $HIMS members and $HIMS shareholders. $HIMS now selling $LLY GLPs which is Tirzepitide. $HIMS already selling the $NVO GLPs which is Semaglutide. This also means that $HIMS members should have access to Retatrutide...
ASCO Grants IDYA Late‑breaker Despite Extensive Prior Data
Given how much $IDYA has already released (ORR, PFS, stats, PFS curves) I'm a little surprised #ASCO26 is OK with giving it a late-breaker.
RG6735 Identified as New $RHHBY Phase‑1 Asset
Any idea what RG6735 is? Looks like a new $RHHBY code for sth that went into phase 1 earlier under a different name. https://t.co/7Cb5Ft2BWC
CEPI Shows Courage; Institutions Must Follow Suit
Many institutions are failing to meet the moment, but not all. @CEPIvaccines proves it has the courage & conviction to carry out essential vaccine work regardless of political pressure for complicity. I wish more institutions would follow their funder’s example.
OSK Reprogramming Restores Adult Heart Regeneration
NEW STUDY: OSK rewinds the clock and pushes adult heart cells into a regenerative state that improves heart repair Why is this such a big deal? Because adult heart cells do not meaningfully divide, which is why the heart heals with scar...
Insilico Launches First Longevity Board to Accelerate AI Aging Research
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery https://t.co/Xd8GpDTVjW
Genetic Bridge Links Ageing Theory to Lifespan Interventions
Dynamics of genetic and somatic trade-offs in ageing and mortality “These findings provide a genetic bridge between evolutionary theories of ageing and molecular mechanisms that can guide interventions to extend healthy lifespan.” https://t.co/HFGnELAIqH https://t.co/gAlE7D4OCh
Crowdfunded Rapamycin‑Exercise Trial Shows Promising Aging Data
Five years ago, @BradStanfieldMD reached out with an idea: a crowdfunded clinical trial testing rapamycin combined with exercise in older adults. The results are now published — and Brad and I just sat down for a full 42-minute breakdown...
Columnless Midiprep: Pool Minipreps, Elute at Quarter Volume
Nice. Good midiprep. Gonna use this for some gene gun optimizations. All columnless, simply combining a few minipreps and eluting in ¼th volume. https://t.co/0unMuxJTIc
Fenebrutinib Shows Promise, Yet Safety Concerns Loom
Relevant to $TGTX was the Roche $RHHBY fenebrutinib trial results recently announced. Excellent efficacy, but two cases of Hy's Law. Both resolved, but a patient might not be so lucky next time. Hard for me to see this gaining widespread...
TGTX Shows Consistently Low Relapse Rates Across Trials
This very low relapse rate in this $TGTX Phase IV observational trial is consistent with that seen in their 6-year extension study: https://t.co/Shvb8h8VRr
AI Discovers Chromogranin A Shields Brains From Alzheimer’s
20 to 30% of older adults have full blown Alzheimer's pathology in their brains (plaques, tangles etc.). But they never develop symptoms and nobody knew why. An AI just read thousands of human brains and named the reason: a protein...
Paxlovid Showed No Hospitalization Benefit in Vaccinated Seniors
In 2 randomized, open-label trials of Paxlovid there was lack of evidence of reduced hospitalizations among the participants, who were age 50+ with coexisting conditions, and who were vaccinated. The endpoint was very low (<1.2%) in the treatment and control...
25% Beta‑Cell Loss and Aging Drive Type 2 Diabetes
Researchers analyzed ~250,000 pancreatic islet cells and found that in type 2 diabetes, about 25% of insulin-producing beta cells are lost and many of the remaining ones become aged and dysfunctional. They identified dozens of genes—along with pathways like vitamin...
Top Protein Degrader Session at AACR26 Highlights Await
Excellent protein degrader session today at #AACR26. Third speaker was all Do Not Post (sorry @HartungIngo !) so some highlights from the other three speakers coming up...
Alzheimer's Drugs Show Minimal Benefit, Review Reveals Deeper Issues
Alzheimer’s drugs offer little benefit, major review finds – and the reasons go deeper than the science https://t.co/cnMPAEQumY https://t.co/wtg8llquON
FDA Criticizes Replimune's Melanoma Trial Design
Some observers, including @US_FDA, have criticized @Replimune for the design of the trial that led to the decision not to grant accelerated approval of their melanoma treatment. I asked the company's Chairman about that view. Watch the full interview: https://t.co/XYVmSeodLv https://t.co/OO8eXTZOXh
Kailera Leads, SANA Ranks #2 Among Biggest Biotech IPOs
The excellent @biospace 📊👇shows the 5 biggest IPOs in BioTech history. At the top of this list is of course Kailera Therapeutics $KLRA with its $625M blockbuster IPO - the largest public offering in recent years. The one that caught...
Food, Not Pills, May Solve Obesity and Heart Disease
The next breakthrough in managing obesity, heart disease, or cognitive decline might not come from a pill. It might come from your food. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your...
PK/PD Crucial for Next-Gen ADC Development
Wonderful tour de force on ADCs by @raffcolo highlighting the importance of PK/PD going forward with new formats https://t.co/nUpBNNoVil
Moderna Launches mRNA Bird Flu Trial After Funding Loss
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial https://t.co/cKyC9jfWAj by Kristin Jensen $MRNA
Cast SDS-PAGE Gels Using Riboflavin, No TEMED
Here is an alternative way to cast SDS-PAGE gels without needing TEMED, using riboflavin, EDTA, and LED lights. Seems very DIY friendly too.
Prelude Tx Unveils Early-Stage KAT6A Degrader
Looking through my #aacr26 collection of posters from yesterday. Prelude Tx have a KAT6A degrader (PRT13722) in early development to compete with inhibitors: https://t.co/23zBtCX8Hs
Personalized CRISPR Poised to Become Standard Care
How individualized CRISPR genome editing can go from rare, expensive use to broader accessibility and a standard of care by @UrnovFyodor and Sadik Kassim @Nature https://t.co/ddc5ASPPAK https://t.co/GOFneIyuai
Sex Chromosomes Drive Cancer, Autoimmunity, and Brain Disease
Our X and Y chromosomes play a bigger part in health than acknowledged, including cancer, autoimmunity, and neurologic conditions. A new @nature feature https://t.co/IjVNbXzBPB
Merck Expands AI Push; Roche Reports MS Drug Data
Merck adds to pharma’s AI push; Roche details MS drug results https://t.co/VmpWyLhP9A $MRK $RHHBY $TGTX $RCUS $GILD #biotech
New Receptor Enables Bat Alphacoronavirus Entry Into Humans
Discovery of a new receptor by which alphacoronavirus from bats can get into human cells and the potential for transmission https://t.co/LE5sTVyfkS @Nature https://t.co/aszqnDMQqE @NatureNV https://t.co/ejnvrvr6BO
AI‑Designed Enzymes Accelerate Corporate Partnerships at SynBioBeta
@SynBioBeta isn't just where startups find investors. It's where Fortune 500 companies find their next technology partner. @IFF is one of the world's largest flavor, fragrance, and biosciences companies, with over $11 billion in revenue and a century-long track record of...
VR Therapy Shows Promise for IBS Treatment
Most people think of VR as gaming. In clinic, we’re using it to help patients manage IBS—alongside meds and diet. We’re looking forward to presenting results from our first IBS randomized controlled trial at #DDW26 in Chicago Non-drug therapies are having a moment. @DDWMeeting...
FDA Approval Could Ignite Peptide Boom and Doping Grey Zone
Peptide space is going to blowup if FDA approves it. Interesting grey area for sports doping.
Redefining ‘First‑in‑Class’ Amid Faster Competing Therapies
How do we define “first in class” when there are others further ahead? This example is from Atheron Therapeutics w/ a CCNE1 degrader #aacr26 https://t.co/s22biREUrt
CDC Vaccine Efficacy Report on Halved Winter Hospitalizations Shelved
The #CDC report that showed the #Covid vaccine halved the risk of a recipient needing emergency care or hospitalization this winter has been shelved by HHS, @bylenasun reports. https://t.co/tCNx8LSIKn